Cargando…

Ocular-Surface Regeneration Therapies for Eye Disorders: The State of the Art

The ocular surface is a complex structure that includes cornea, conjunctiva, limbus, and tear film, and is critical for maintaining visual function. When the ocular-surface integrity is altered by a disease, conventional therapies usually rely on topical drops or tissue replacement with more invasiv...

Descripción completa

Detalles Bibliográficos
Autores principales: Posarelli, Matteo, Romano, Davide, Tucci, Davide, Giannaccare, Giuseppe, Scorcia, Vincenzo, Taloni, Andrea, Pagano, Luca, Borgia, Alfredo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10295950/
https://www.ncbi.nlm.nih.gov/pubmed/37366796
http://dx.doi.org/10.3390/biotech12020048
_version_ 1785063542413590528
author Posarelli, Matteo
Romano, Davide
Tucci, Davide
Giannaccare, Giuseppe
Scorcia, Vincenzo
Taloni, Andrea
Pagano, Luca
Borgia, Alfredo
author_facet Posarelli, Matteo
Romano, Davide
Tucci, Davide
Giannaccare, Giuseppe
Scorcia, Vincenzo
Taloni, Andrea
Pagano, Luca
Borgia, Alfredo
author_sort Posarelli, Matteo
collection PubMed
description The ocular surface is a complex structure that includes cornea, conjunctiva, limbus, and tear film, and is critical for maintaining visual function. When the ocular-surface integrity is altered by a disease, conventional therapies usually rely on topical drops or tissue replacement with more invasive procedures, such as corneal transplants. However, in the last years, regeneration therapies have emerged as a promising approach to repair the damaged ocular surface by stimulating cell proliferation and restoring the eye homeostasis and function. This article reviews the different strategies employed in ocular-surface regeneration, including cell-based therapies, growth-factor-based therapies, and tissue-engineering approaches. Dry eye and neurotrophic keratopathy diseases can be treated with nerve-growth factors to stimulate the limbal stem-cell proliferation and the corneal nerve regeneration, whereas conjunctival autograft or amniotic membrane are used in subjects with corneal limbus dysfunction, such as limbal stem-cell deficiency or pterygium. Further, new therapies are available for patients with corneal endothelium diseases to promote the expansion and migration of cells without the need of corneal keratoplasty. Finally, gene therapy is a promising new frontier of regeneration medicine that can modify the gene expression and, potentially, restore the corneal transparency by reducing fibrosis and neovascularization, as well as by stimulating stem-cell proliferation and tissue regeneration.
format Online
Article
Text
id pubmed-10295950
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-102959502023-06-28 Ocular-Surface Regeneration Therapies for Eye Disorders: The State of the Art Posarelli, Matteo Romano, Davide Tucci, Davide Giannaccare, Giuseppe Scorcia, Vincenzo Taloni, Andrea Pagano, Luca Borgia, Alfredo BioTech (Basel) Review The ocular surface is a complex structure that includes cornea, conjunctiva, limbus, and tear film, and is critical for maintaining visual function. When the ocular-surface integrity is altered by a disease, conventional therapies usually rely on topical drops or tissue replacement with more invasive procedures, such as corneal transplants. However, in the last years, regeneration therapies have emerged as a promising approach to repair the damaged ocular surface by stimulating cell proliferation and restoring the eye homeostasis and function. This article reviews the different strategies employed in ocular-surface regeneration, including cell-based therapies, growth-factor-based therapies, and tissue-engineering approaches. Dry eye and neurotrophic keratopathy diseases can be treated with nerve-growth factors to stimulate the limbal stem-cell proliferation and the corneal nerve regeneration, whereas conjunctival autograft or amniotic membrane are used in subjects with corneal limbus dysfunction, such as limbal stem-cell deficiency or pterygium. Further, new therapies are available for patients with corneal endothelium diseases to promote the expansion and migration of cells without the need of corneal keratoplasty. Finally, gene therapy is a promising new frontier of regeneration medicine that can modify the gene expression and, potentially, restore the corneal transparency by reducing fibrosis and neovascularization, as well as by stimulating stem-cell proliferation and tissue regeneration. MDPI 2023-06-15 /pmc/articles/PMC10295950/ /pubmed/37366796 http://dx.doi.org/10.3390/biotech12020048 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Posarelli, Matteo
Romano, Davide
Tucci, Davide
Giannaccare, Giuseppe
Scorcia, Vincenzo
Taloni, Andrea
Pagano, Luca
Borgia, Alfredo
Ocular-Surface Regeneration Therapies for Eye Disorders: The State of the Art
title Ocular-Surface Regeneration Therapies for Eye Disorders: The State of the Art
title_full Ocular-Surface Regeneration Therapies for Eye Disorders: The State of the Art
title_fullStr Ocular-Surface Regeneration Therapies for Eye Disorders: The State of the Art
title_full_unstemmed Ocular-Surface Regeneration Therapies for Eye Disorders: The State of the Art
title_short Ocular-Surface Regeneration Therapies for Eye Disorders: The State of the Art
title_sort ocular-surface regeneration therapies for eye disorders: the state of the art
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10295950/
https://www.ncbi.nlm.nih.gov/pubmed/37366796
http://dx.doi.org/10.3390/biotech12020048
work_keys_str_mv AT posarellimatteo ocularsurfaceregenerationtherapiesforeyedisordersthestateoftheart
AT romanodavide ocularsurfaceregenerationtherapiesforeyedisordersthestateoftheart
AT tuccidavide ocularsurfaceregenerationtherapiesforeyedisordersthestateoftheart
AT giannaccaregiuseppe ocularsurfaceregenerationtherapiesforeyedisordersthestateoftheart
AT scorciavincenzo ocularsurfaceregenerationtherapiesforeyedisordersthestateoftheart
AT taloniandrea ocularsurfaceregenerationtherapiesforeyedisordersthestateoftheart
AT paganoluca ocularsurfaceregenerationtherapiesforeyedisordersthestateoftheart
AT borgiaalfredo ocularsurfaceregenerationtherapiesforeyedisordersthestateoftheart